BioCentury
ARTICLE | Product Development

Investors act early as pharmacodynamic data drive Morphic shares

Positive data could read through to rest of Morphic’s pipeline

March 2, 2021 12:57 AM UTC

With pharmacodynamic data driving a gain of over $1.6 billion in market cap, Morphic is the latest example of how deep insights into structural biology are pushing clinical inflection points earlier. 

Shares of Morphic Holding Inc. (NASDAQ:MORF) rose 135% to $84.85 on Monday after the company said lead oral integrin inhibitor MORF-057 achieved receptor occupancy levels of greater than 95% in a Phase I study, in addition to being safe. The move brings the company’s market cap to more than $2.6 billion...



Access The Full Article

BCIQ Company Profiles

Morphic Holding Inc.

BCIQ Target Profiles

Integrin alpha(4)beta(7)